The company posted a loss of $4 million, or 22 cents a share, a significant expansion from the $859,000 loss recorded during the same period last year. Revenue mirrored this downward trend, sliding to $582,000 from $1.32 million, with the bulk of earnings still derived from research and development contracts.

Aeluma is now pivoting away from early-stage government R&D projects toward commercial scale. This strategy relies heavily on a July letter of intent with the Commerce Department, which could provide up to $30 million in Chips Act funding. CEO Jonathan Klamkin stated that fiscal 2027 will prioritize product development and expanding customer engagement, specifically targeting AI datacom firms to secure non-recurring engineering agreements.